Condition: Clear Cell Renal Cell Carcinoma · Sponsor: University of Oklahoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
This description comes directly from the study's public registry record.
Ingrid Block · 405-271-8777 · SCC-IIT-Office@ouhsc.edu
Lead Nurse · 405-271-8777 · SCC-IIT-Office@ouhsc.edu
Always discuss trial participation with your own doctor first.
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223541